cagrisema phase 3 results 2025 semaglutide cagrilintide obesity Novo Nordisk shares plunge after drug trial disappoints Novo Nordisk's CagriSema outperforms Ozempic
Novo Nordisk's CagriSema outperforms Ozempic in Phase III trial cagrisema cagrilintide semaglutide phase 3 results 2024 2025 Novo Nordisk's stock drops despite hitting goal of III trial Presenters to provide first look Novo's CagriSema loses phase 3 obesity battle against Zepbound What is cagrisema and how does it work for weight loss? Coadministered Cagrilintide and Semaglutide, in Adults with Overweight or Obesity. June 22,, 2025. DOI: 10.1056 NEJMoa2502081, CagrilintideSemaglutide in Adults with, Overweight or Obesity and Type 2
Pay in 4 interest-free payments of $6.30 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7



